Abstract
The effectiveness of overactive bladder treatment with M-cholinoblocker solifenacin (Vesicare) as monotherapy and in combination with α1-andrenoblocker terazosin (Setegis) or bladdrer training in elderly patients was evaluated. The results of 12 weeks treatment in all treatment modality groups were comparable. Use of solifenacin in combination with α1-andrenoblocker in comparison to solifenacin monotherapy resulted in longer symptoms remission.
MeSH terms
-
Adrenergic alpha-1 Receptor Antagonists / administration & dosage
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Muscarinic Antagonists / administration & dosage
-
Prazosin / administration & dosage
-
Prazosin / analogs & derivatives*
-
Quinuclidines / administration & dosage*
-
Solifenacin Succinate
-
Tetrahydroisoquinolines / administration & dosage*
-
Treatment Outcome
-
Urinary Bladder, Overactive / diagnosis
-
Urinary Bladder, Overactive / drug therapy*
-
Urinary Bladder, Overactive / physiopathology
-
Urination / drug effects
Substances
-
Adrenergic alpha-1 Receptor Antagonists
-
Muscarinic Antagonists
-
Quinuclidines
-
Tetrahydroisoquinolines
-
Terazosin
-
Solifenacin Succinate
-
Prazosin